65,437 trials
Dry Eye Disease
Primary: Change From Baseline to Day 29 in Corneal Fluorescein Staining Score in the Study Eye — 2.19; 2.31 score on a scale — p=0.315
Stroke · Exercise
Primary: Ratio of Average Activity Duration (RAAD) — 1.223 ratio
Growth Hormone Disorder · Growth Hormone Deficiency in Children
Primary: Height Velocity (HV) (cm/Year) During the First 26 Weeks of Treatment, Measured as Standing Height With Stadiometer — 11.35; 7.96; 10.92; 12.88 Centimetre per year…
Stimulant Dependence · Methamphetamine-dependence · Addiction, Drug
Primary: Retention in the Study — 28.2; 45.4 Days — p=0.1760
Aging · Mild Cognitive Impairment · Aging Well
Primary: Change in Social Isolation Measured by Friendship Scale — 20.37; 20.54; 20.05; 20.23 score on a scale — p=<.05
Parkinson Disease
Primary: Changes From Baseline in Scores of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III (Motor Examination) in Subjects After 12 Weeks of…
Rabies
Primary: Rabies Virus Neutralizing Activity (RVNA) of Geometric Mean Concentration (GMC) at Study Day 8 — 4.70; 0.13; 3.30; 0.17 IU/mL
Cardiometabolic Health
Primary: Systolic Blood Pressure — 127.0; 126.5 mm Hg — p=0.588
Chemotherapy-Induced Peripheral Neuropathy · Malignant Solid Neoplasm
Primary: Change in Chemotherapy-induced Peripheral Neuropathy (CIPN) From Baseline — 147.95; 135.82; 167.96; 148.45 percentage of change in CIPN
Traumatic Brain Injury
Primary: Vital Signs (Respiratory Rate) — 16.54; 16.82; 16.63; 16.42 breaths/min
Metastatic Pancreatic Adenocarcinoma
Primary: Overall Survival — 6.4; 5.9 months
Pulmonary Disease, Chronic Obstructive
Primary: Chronic Obstructive Pulmonary Disease (COPD) Exacerbations of Sensor-collected Parameters During Observation Period - Physical Activity — 41.98; 58.93 minutes
Bladder Cancer
Primary: Proportion of Patients Experiencing Severe Acute Non-genitourinary Side Effects Following Radiotherapy. — 4; 2 Participants
Hematologic Malignancy · Myelodysplastic Syndromes · Acute Myeloid Leukemia
Primary: Proportion of Eligible Patients Choosing to Participate in the Care Model Under Study Rather Than Standard of Care. — 10 Participants
Healthy
Primary: Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero Extrapolated to Infinity (AUC0-inf) of Evobrutinib — 310; 49.2 Hour*nanograms per milliliter (h*ng/mL)